- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00388284
Safety and Efficacy Study Comparing Thrombin for Arterial Sealing
Comparative Analysis of Thrombin Utilized in Endovascular Procedures of the Femoral Artery - CEASE Study
This trial is designed as a prospective, multi-center, randomized, double blinded clinical trial to evaluate the safety and efficacy of the Thrombin VSI. An immunological sub-study to assess antibody and coagulation changes in the subjects following exposure to the Vascular Solutions Diagnostic Duett Pro manufactured with Thrombin VSI and Thrombin JMI will be conducted as a component of this trial with a subset of the enrolled study subjects.
Two hundred seventy (270) subjects will be enrolled in this trial. A minimum of 50% of the subjects will be interventional subjects and up to 50% will be diagnostic subjects. All 270 subjects will provide blood specimens at baseline and at the 30 day follow-up visit for evaluation in the immunologic sub-study. Within the 270 subjects enrolled, a minimum of 45 subjects treated with the Thrombin VSI and a minimum of 45 subjects treated with the Thrombin JMI will provide blood specimens at the 60 day follow-up visit to be evaluated in the immunologic sub-study.
The primary efficacy objective is to demonstrate that the device time-to-hemostasis for the study group treated with the sealing device manufactured with Thrombin VSI is non-inferior to the study group treated with the sealing device manufactured with Thrombin JMI.
The primary safety objective is to demonstrate a device-related major complication rate for the study group treated with the sealing device manufactured with Thrombin VSI that is non-inferior to the device-related major complication rate observed for the study group treated with the sealing device manufactured with Thrombin JMI.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Florida
-
Safety Harbor, Florida, United States, 34695
- The Heart and Vascualr Institute of Florida
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27610
- WakeMed
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Mary Washington Hospital
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
- Charleston Area Medica Center (CAMC)
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is 18 years of age or older
- The subject is undergoing a diagnostic or interventional endovascular procedure via a retrograde femoral arterial access
- The subject is willing and able to provide appropriate informed consent
- The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow-up evaluations
Exclusion Criteria:
Exclusion criteria determined prior to procedure:
The subject has a history of clinically severe peripheral vascular disease documented as any of the following:
- Severe claudication (walking < 100 feet)
- Absent pulses in the affected limb
- ABI < 0.5 at rest
- Known diameter stenosis ≥ 50% in the iliac or femoral artery on the affected side
- Prior vascular bypass surgery involving the affected femoral artery
- Prior stent placement in the vicinity of the arterial puncture site
- The subject is known to be, or suspected to be, pregnant (verified in a manner consistent with institution's standard of care), or is lactating
- The subject has a pre-existing severe non-cardiac systemic disease or pre-existing terminal illness
- The subject has had an acute myocardial infarction ≤ 72 hours before the catheterization procedure
- The subject is unable to ambulate at baseline
- The subject is known to require an extended hospitalization (e.g., subject is undergoing CABG surgery)
- The subject has a known bleeding disorder (including thrombocytopenia [< 100,000 platelet count], thrombobasthenia, hemophilia, or von Willebrand disease)
- The subject is receiving Coumadin/warfarin therapy and has an INR > 2.0 on the day of, or the day before the study procedure. (INR of > 2.0 should not result in a dose change prior to the study procedure. If dosage changed, test should be repeated prior to the procedure)
- The subject has a known allergy to bovine derived products or any other materials used in the Diagnostic Duett Pro Sealing Device
- The subject has undergone prior use of a closure device in the ipsilateral common femoral artery ≤ 6 months before the current catheterization procedure
- The subject has undergone prior use of manual compression for closure in the ipsilateral common femoral artery ≤ 6 weeks before the current catheterization procedure
- The subject has undergone current, recent, or prior use of an intra-aortic balloon pump through the existing arterial puncture site
- The subject is unavailable for follow-up
- The subject is currently participating in another investigational device or drug trial
- The subject has previously participated in this trial (Protocol 0106)
Exclusion criteria to be determined during the procedure:
- The subject has an antegrade puncture
- The subject's arterial introducer sheath is <5F or > 9F or longer than 15.2 cm in overall length
- The subject has a suspected posterior femoral arterial wall puncture or puncture distal to the common femoral artery bifurcation
- The subject's common femoral artery diameter is estimated to be < 6 mm via angiogram
- The subject has tortuous vascular anatomy with greater than 90o bends on femoral angiogram
- The subject is severely hypertensive (defined as systolic BP > 180 mmHg or diastolic BP > 110 mmHg)
- The subject has experienced hemodynamic instability, defined as systolic blood pressure < 90 mmHg or cardiogenic shock, during or immediately post-procedure
- The subject has been anticoagulated with unfractionated heparin and has an ACT of > 300 seconds at completion of the antecedent procedure
- The subject is anticipated to continue dosing of heparin or anti-coagulant therapy (except any approved GPIIb/IIIa platelet receptor blocker) ≤ 6 hours following completion of the interventional or diagnostic procedure
- The subject has received thrombolytic therapy (e.g., streptokinase, urokinase, or t-PA) ≤ 24 hours prior to the catheterization procedure
- The subject has a large hematoma (≥ 6cm in diameter) present prior to vascular sealing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Time to Hemostasis
|
Incidence rate of device-related major complications
|
Secondary Outcome Measures
Outcome Measure |
---|
Minor complications
|
Subject satisfaction
|
Time to ambulation
|
Procedure success
|
Device success
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 0106
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemostasis of Arterial Punctures
-
Second Xiangya Hospital of Central South UniversityCompleted
-
Unity Health TorontoUnknownArterial Hemostasis After Coronary InterventionCanada
-
University Hospital, BrestCompletedPreoperative Assessment of HemostasisFrance
-
Oslo University HospitalHelse Sor-OstCompletedHemostasis | Injury of Radial Artery | Peripheral Artery OcclusionNorway
-
Southwest Hospital, ChinaWest China Second University HospitalCompletedRadiofrequency Can be Used to Treat Splenic Trauma Because of Its Excellent Coagulation HemostasisChina
-
Terumo Europe N.V.CompletedPeripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular ProcedureBelgium, France, Germany
-
Aesculap AGCompletedPeripheral Vascular Diseases | HemostasisGermany
-
Terumo Europe N.V.Terumo Medical CorporationRecruitingPeripheral Vascular Disease | Hemostasis | Vascular Closure | Femoral Artery | Endovascular ProcedureFrance, Germany, Netherlands
-
Coramed Technologies LLCCompletedHeart Disease | Focus is on Testing Performance of CORA Hemostasis System.United States
-
University of Colorado, DenverCompletedConscious Sedation | Simple Lacerations Less Than 4 cm | Lumbar Punctures | Minor Incision Drainage of Abscesses Not Requiring Extensive DebridementUnited States
Clinical Trials on Arterial Sealing
-
Cairo UniversityUnknown
-
Marlana McDowellTriHealth Hatton Research InstituteActive, not recruiting
-
Hams Hamed AbdelrahmanCompletedSoft Tissue HealingEgypt
-
Ospedale Regina ApostolorumAzienda Ospedaliera San Gerardo di Monza; San Giuseppe Moscati Hospital; Ospedali...UnknownEfficacy of Hemopatch in Controlling of Postoperative Bleeding or Reducing of Postperative Morbidity After Laparoscopic CholecistectomyItaly
-
Ain Shams UniversityTerminated
-
Aarhus University HospitalCompleted
-
University of Milano BicoccaCompletedAxilla Node DissectionItaly
-
Memorial Sloan Kettering Cancer CenterCompletedCervical Cancer | Ovarian Cancer | Uterine CancerUnited States
-
Shanghai Changzheng HospitalCompleted
-
Cairo UniversityNot yet recruiting